Anita Kumar, MD | Authors

The Emerging Role of Checkpoint Inhibitor Therapy in Hodgkin Lymphoma

October 15, 2016

Ultimately, the management goal is not for patients with relapsed/refractory disease to live with chronic Hodgkin lymphoma while receiving immune checkpoint blockade therapy, but rather to cure more patients with first- or second-line therapy.